Prospects of Targeting PI3K/AKT/mTOR Pathway in Pancreatic Cancer

Scientists report that whole-genome analyses demonstrate the frequent involvement of aberrant activations of PI3K/AKT/mTOR pathway components in PDAC patients and critically evaluate preclinical and clinical evidence on the application of PI3K/AKT/mTOR pathway targeting agents.